- Graham MF, Diegelmann RF, Elson CO, Lindblad WJ, Got schal k N, Gay S, et al. Collagen content and types in the intestinal strictures of Crohn's disease. Gastroenterology 1988; 94:257-65.
- Matthes H, Herbst H, Schuppan D, Stallmach A, Milani S, Stein H, Riecken E-O. Cellular localization of procollagen gene transcripts in inflammatory bowel disease. Gastroenterology 1992:102:431 -42.
- Stallmach A, Schuppan D, Riese HH, Matthes H, Riecken EO. Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease. Gastroenterology 1992:102:1920-9.
- Graham MF, Drucker EM, Diegelmann RF, Elson CO. Collagen synthesis by human intestinal smooth muscle cells in culture. Gastroenterology 1987;92:400-5.
- Pucilowska JB, Williams KL, Lund PK. Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol 2000; 279:0653-9.
- Risteli L, Risteli J. Biochemical markers of bone metabolism. Ann Med 1993;25:385-93.
- Teare JP, Sherman D, Greenfield SM, Simpson J, Bray G, Catterall AP, et al. Comparison of serum procollage III peptide concentration s and PGA index for assessment of hepatic fibrosis. Lancet 1993;342:895-8.
- Loeschke K, Kaltenthaler P. Prokollagen-III-Pepti d im serum bei patienten mit M. Crohn. Z Gastroenterol 1989;27:137-9.
- Colombel JF, Hällgren R, Engström-Laurent A, Rambaud JC. Hyaluronic acid and type UI procollage n peptide in jejunal perfusion fluid as markers of connective tissue turnover. Gastroenterology 1989:96:68-73.
- Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992;66:337-41.
- Hørslev-Petersen K, Bentsen KD, Engström-Laurent A, Junker P, Halberg P, Lorenzen I. Serum amino terminal III procollage n peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' therapy with levamisole, penicillamine, or azathioprine. Ann Rheum Dis 1988;47:116-26.
- Hørslev-Petersen K, Bentsen KD, Junker P, Lorenzen I. Serum amino-terminal type III procollage n peptide in rheumatoid arthritis. Arthritis Rheum 1986;29:592-9.
- Sassi ML, Eriksen H, Risteli L, Niemi S, Mansel LJ, Gowen M, et al. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 2000;26: 367-73.
- Kjeldsen J, Schaffalitzky de Muckadel 1OB, JunkerP. Seromarkers of collagen I and III metabolism in active Crohn ' s disease. Relation to disease activity and response to therapy. Gut 1995;37805-10.
- Malchow H, Ewe K, Brandes JW, Goebell LH, Ehms H, Sommer H, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86: 249-66.
- Risteli J, Niemi S, Trivedi P, Mäentausta O, Mowat AP, Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem 1988;34: 715-8.
- Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990;36:1328-32.
- Gram J, Bollerslev J, Nielsen HK, Junker P. Increased serum concentrations of type I procollagen C-terminal propeptide and osteocalcin during a short course of calchriol administration to adult male volunteers. Acta Endocrine 1 1991; 125:609-13.
- Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993;39:635-40.
- Siegel S, Castellan NJJ. Nonparametric statistics for the behavioral sciences, 2nd ed. New York: McGraw-Hill International; 1988.
- Smedsrød B, Melkko J, Risteli L, Risteli J. Circulating Cterminal propeptide of type I procollage n is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 1990; 271:345-50.
- Melkko J, Hellevik T, Risteli L, Risteli J, Smedsrød B. Clearance of NH2-terminal propeptide s of types I and ID procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 1994; 179:405-12.
- Hansen M, Stoltenberg M, Høst NB, Boesby S, Lorenzen I, Bentsen KD. Glucocorticoids inhibit the synthesis rate of type III collagen, but do not affect the hepatic clearance of its aminoterminal propeptide (PIIINP). Scand J Clin Lab Invest 1995:55:543-8.
- Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 1993;8:127-32.
- Charles P, Mosekilde L, Risteli L, Risteli J, Eriksen EF. Assessment of bone remodelling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner 1994;24:81-94.
- Silvennoinen J, Risteli L, Karttunen T, Risteli J. Increased degradation of type I collagen in patients with inflammatory bowel disease. Gut 1995;38:223-8.
- Mø11er S, Hansen M, Hillingsø J, Jensen J-EB, Henriksen JH. Elevated carboxy terminal cross linked telopeptide of type I collagen in alcoholic cirrhosis: relation to liver and kidney function and bone metabolism. Gut 1999;44:417-23.
Scandinavian Journal of Gastroenterology
Volume 36, 2001 - Issue 11